At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
pazopanib hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma
In Brief
A Phase 2 clinical trial evaluating pazopanib hydrochloride and laboratory biomarker analysis for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 35 participants across 9 sites.
Detailed Summary
This phase II trial is studying the side effects and how well pazopanib works in treating patients with recurrent glioblastoma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartMay 2007
Primary CompletionDec 2008
TodayJul 2026
First PostedApr 11, 2007
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.2 years ago
Interventions
pazopanib hydrochloridedrug
Given orally
laboratory biomarker analysisother
Correlative studies